Publication at Second Faculty of Medicine, Third Faculty of Medicine |
2019
Abstract
Hypoglycaemia is a consistent risk of the type 2 diabetes (T2DM) therapy, especially insulin or some older oral hypoglycaemic agents as the insulin secretagogues. It is also associated with various range of health disorders, increased cardiovascular risk or death.
Hypoglycaemia can present with diverse symptoms or can be asymptomatic. Almost 10% of patients with T2DM suffer from hypoglycaemia unawareness.
The risk of hypoglycaemia is associated with a level of glycaemic control and increases also with age, comorbidities and strength of diabetes therapy. Warning value, in which patients with diabetes should considered initiation of appropriate therapeutic steps, is the level of glycaemia 3.9 mmol/l.